# US 2001/0013134 A1 · Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0013134 A1
- Document ID: US20010013134A1
- Status: Published application
- Kind: A1
- Application number: 09/826,779
- Filed: 2001-04-05
- Published: 2001-08-09
- Earliest claimed: 1998-12-16
- Inventors: Nora Sarvetnick; Michelle L. Krakowski; Marcie R. Kritzik
- Web page: https://patentgrep.com/patent/US20010013134A1

## CPC

- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 67/0271: Chimeric vertebrates, e.g. comprising exogenous cells
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A61K 38/1808: {Epidermal growth factor [EGF] urogastrone}
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- C07K 16/18: against material from animals or humans
- C12N 5/0672: {Stem cells; Progenitor cells; Precursor cells; Oval cells}
- C12N 5/0676: {Pancreatic cells}
- C12N 5/0678: {Stem cells; Progenitor cells; Precursor cells}
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2227/105: Murine
- A01K 2267/03: Animal model, e.g. for test or diseases
- A01K 2267/0325: Animal model for autoimmune diseases
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/117: Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
- C12N 2503/00: Use of cells in diagnostics
- C12N 2517/02: Cells from transgenic animals
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides animal models, where the ectopic expression of KGF, EGF, or both is under the control of a pancreas-specific promoter, e.g., the insulin promoter. The expression of KGF in the ins-KGF pancreatic islets of Langerhans results in enlarged islets, with substantial proliferation of duct cells within the islet mass, and the presence of albumin and alpha-fetoprotein-producing hepatocytes in the islets of the ins-KGF pancreata. The compositions and methods disclosed are useful for identifying and isolating pancreatic stem/progenitor cells, including a common stem/progenitor to liver cells and pancreatic cells.

## Claims

### Claim 1

A transgenic non-human mammal, whose cells contain a polynucleotide, comprising:
a pancreas-specific promoter operably linked to a KGF-coding polynucleotide.

### Claim 2 (depends on 1)

The transgenic mammal of claim 1 wherein the pancreas-specific promoter is an insulin promoter.

### Claim 3 (depends on 1, 2)

The mammal of claim 1 or 2, whose cells further contain a polynucleotide, comprising:
a second pancreas-specific promoter operably linked to an EGF-coding polynucleotide.

### Claim 4 (depends on 1, 2)

The mammal of claim 1 or 2, whose cells further contain a polynucleotide, comprising:
an insulin promoter operably linked to an EGF-coding polynucleotide promoter.

### Claim 5

A method for the in vivo proliferation of pancreatic duct cells in a mammal, comprising:
providing a pancreatic source of KGF to the mammal.

### Claim 6

A method for in vivo production of pancreatic hepatocytes in a mammal, comprising:
providing a pancreatic source of KGF to the mammal.

### Claim 7 (depends on 5, 6)

The methods of claim 5 or 6, wherein the pancreatic source of KGF is provided by expression of a recombinant DNA molecule comprising a pancreatic specific promoter operably linked to a KGF-coding polynucleotide.

### Claim 8

A method for producing pancreatic duct cells, comprising
contacting a common stem/progenitor cell to liver cells and pancreatic cells with a developmentally effective amount of KGF, wherein KGF induces common stem/progenitor cells to develop to duct cells.

### Claim 9

A method for producing amylase-positive exocrine cells, comprising
contacting a common stem/progenitor to liver cells and pancreatic cells with a developmentally effective amount of KGF, wherein KGF induces common stem/progenitor cells to develop to exocrine cells.

### Claim 10

A method for the in vivo proliferation of a common stem/progenitor to liver cells and pancreatic cells, comprising
providing a pancreatic source of KGF a proliferation-inducing growth factor to a mammal, wherein the growth factor is the expression product of a polynucleotide having a pancreatic-specific promoter operably linked with a coding polynucleotide for the growth factor.

### Claim 11 (depends on 10)

The method of claim 10, wherein the pancreatic-specific promoter is an insulin promoter.

### Claim 12

A method for inhibiting beta cell development in the pancreas of a mammal, comprising:
injecting the subject with an inhibition-effective amount of a neutralizing α-KGF antibody.

### Claim 13

A method for identifying proliferating pancreatic duct cells using PDX-1 as a marker, comprising:
(a) contacting a pancreatic duct containing proliferating pancreatic duct cells with a reagent that binds to PDX-1 and
(b) detecting the contact, wherein the detection identifies the duct as containing proliferating pancreatic duct cells.

### Claim 14 (depends on 13)

The method of claim 13, wherein the reagent is an anti-PDX-1 antibody.

### Claim 15 (depends on 13)

The method of claim 13, wherein the detection is of contact between the reagent and PDX-1 in a proliferating pancreatic duct cell.

### Claim 16 (depends on 13)

The method of claim 13, wherein the proliferating pancreatic duct cell is a pancreatic stem/progenitor cell.

### Claim 17 (depends on 16)

The method of claim 16, wherein the detection is of contact between the reagent and PDX-1 in a pancreatic stem/progenitor cell.
